Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
[No title available]

Cancer discovery

Ciampricotti M, Karakousi T, Richards AL, Quintanal-Villalonga À, Karatza A, Caeser R, Costa EA, Allaj V, Manoj P, Spainhower KB, Kombak FE, Sanchez-Rivera FJ, Jaspers JE, Zavitsanou AM, Maddalo D, Ventura A, Rideout WM, Akama-Garren EH, Jacks T, Donoghue MTA, Sen T, Oliver TG, Poirier JT, Papagiannakopoulos T, Rudin CM.
PMID: 34344693
Cancer Discov. 2021 Aug 03; doi: 10.1158/2159-8290.CD-21-0441. Epub 2021 Aug 03.

Small cell lung cancer (SCLC) has limited therapeutic options and an exceptionally poor prognosis. Understanding the oncogenic drivers of SCLC may help define novel therapeutic targets. Recurrent genomic rearrangements have been identified in SCLC, most notably an in-frame gene...

Cite
Ciampricotti M, Karakousi T, Richards AL, et al. . Cancer Discov. 2021;doi: 10.1158/2159-8290.CD-21-0441.
Ciampricotti, M., Karakousi, T., Richards, A. L., Quintanal-Villalonga, �. �., Karatza, A., Caeser, R., Costa, E. A., Allaj, V., Manoj, P., Spainhower, K. B., Kombak, F. E., Sanchez-Rivera, F. J., Jaspers, J. E., Zavitsanou, A. M., Maddalo, D., Ventura, A., Rideout, W. M., Akama-Garren, E. H., Jacks, T., Donoghue, M. T. A., Sen, T., Oliver, T. G., Poirier, J. T., Papagiannakopoulos, T., & Rudin, C. M. (2021). . Cancer discovery, . https://doi.org/10.1158/2159-8290.CD-21-0441
Ciampricotti, Metamia, et al. "." Cancer discovery vol. (2021). doi: https://doi.org/10.1158/2159-8290.CD-21-0441
Ciampricotti M, Karakousi T, Richards AL, Quintanal-Villalonga À, Karatza A, Caeser R, Costa EA, Allaj V, Manoj P, Spainhower KB, Kombak FE, Sanchez-Rivera FJ, Jaspers JE, Zavitsanou AM, Maddalo D, Ventura A, Rideout WM, Akama-Garren EH, Jacks T, Donoghue MTA, Sen T, Oliver TG, Poirier JT, Papagiannakopoulos T, Rudin CM. . Cancer Discov. 2021 Aug 03; doi: 10.1158/2159-8290.CD-21-0441. Epub 2021 Aug 03. PMID: 34344693.
Copy Download .nbib Format: NLM
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer.

Cancer cell

Chan JM, Quintanal-Villalonga Á, Gao VR, Xie Y, Allaj V, Chaudhary O, Masilionis I, Egger J, Chow A, Walle T, Mattar M, Yarlagadda DVK, Wang JL, Uddin F, Offin M, Ciampricotti M, Qeriqi B, Bahr A, de Stanchina E, Bhanot UK, Lai WV, Bott MJ, Jones DR, Ruiz A, Baine MK, Li Y, Rekhtman N, Poirier JT, Nawy T, Sen T, Mazutis L, Hollmann TJ, Pe'er D, Rudin CM.
PMID: 34653364
Cancer Cell. 2021 Nov 08;39(11):1479-1496.e18. doi: 10.1016/j.ccell.2021.09.008. Epub 2021 Oct 14.

Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A, -N, and -P, respectively). To define the heterogeneity of tumors and their associated microenvironments across subtypes, we...

Cite
Chan JM, Quintanal-Villalonga Á, Gao VR, et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021;39(11):1479-1496.e18doi: 10.1016/j.ccell.2021.09.008.
Chan, J. M., Quintanal-Villalonga, �. �., Gao, V. R., Xie, Y., Allaj, V., Chaudhary, O., Masilionis, I., Egger, J., Chow, A., Walle, T., Mattar, M., Yarlagadda, D. V. K., Wang, J. L., Uddin, F., Offin, M., Ciampricotti, M., Qeriqi, B., Bahr, A., de Stanchina, E., Bhanot, U. K., Lai, W. V., Bott, M. J., Jones, D. R., Ruiz, A., Baine, M. K., Li, Y., Rekhtman, N., Poirier, J. T., Nawy, T., Sen, T., Mazutis, L., Hollmann, T. J., Pe'er, D., & Rudin, C. M. (2021). Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer cell, 39(11), 1479-1496.e18. https://doi.org/10.1016/j.ccell.2021.09.008
Chan, Joseph M, et al. "Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer." Cancer cell vol. 39,11 (2021): 1479-1496.e18. doi: https://doi.org/10.1016/j.ccell.2021.09.008
Chan JM, Quintanal-Villalonga Á, Gao VR, Xie Y, Allaj V, Chaudhary O, Masilionis I, Egger J, Chow A, Walle T, Mattar M, Yarlagadda DVK, Wang JL, Uddin F, Offin M, Ciampricotti M, Qeriqi B, Bahr A, de Stanchina E, Bhanot UK, Lai WV, Bott MJ, Jones DR, Ruiz A, Baine MK, Li Y, Rekhtman N, Poirier JT, Nawy T, Sen T, Mazutis L, Hollmann TJ, Pe'er D, Rudin CM. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021 Nov 08;39(11):1479-1496.e18. doi: 10.1016/j.ccell.2021.09.008. Epub 2021 Oct 14. PMID: 34653364; PMCID: PMC8628860.
Copy Download .nbib Format: NLM
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer.

Cancer cell

Chan JM, Quintanal-Villalonga Á, Gao VR, Xie Y, Allaj V, Chaudhary O, Masilionis I, Egger J, Chow A, Walle T, Mattar M, Yarlagadda DVK, Wang JL, Uddin F, Offin M, Ciampricotti M, Qeriqi B, Bahr A, de Stanchina E, Bhanot UK, Lai WV, Bott MJ, Jones DR, Ruiz A, Baine MK, Li Y, Rekhtman N, Poirier JT, Nawy T, Sen T, Mazutis L, Hollmann TJ, Pe'er D, Rudin CM.
PMID: 34653364
Cancer Cell. 2021 Nov 08;39(11):1479-1496.e18. doi: 10.1016/j.ccell.2021.09.008. Epub 2021 Oct 14.

Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A, -N, and -P, respectively). To define the heterogeneity of tumors and their associated microenvironments across subtypes, we...

Cite
Chan JM, Quintanal-Villalonga Á, Gao VR, et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021;39(11):1479-1496.e18doi: 10.1016/j.ccell.2021.09.008.
Chan, J. M., Quintanal-Villalonga, �. �., Gao, V. R., Xie, Y., Allaj, V., Chaudhary, O., Masilionis, I., Egger, J., Chow, A., Walle, T., Mattar, M., Yarlagadda, D. V. K., Wang, J. L., Uddin, F., Offin, M., Ciampricotti, M., Qeriqi, B., Bahr, A., de Stanchina, E., Bhanot, U. K., Lai, W. V., Bott, M. J., Jones, D. R., Ruiz, A., Baine, M. K., Li, Y., Rekhtman, N., Poirier, J. T., Nawy, T., Sen, T., Mazutis, L., Hollmann, T. J., Pe'er, D., & Rudin, C. M. (2021). Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer cell, 39(11), 1479-1496.e18. https://doi.org/10.1016/j.ccell.2021.09.008
Chan, Joseph M, et al. "Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer." Cancer cell vol. 39,11 (2021): 1479-1496.e18. doi: https://doi.org/10.1016/j.ccell.2021.09.008
Chan JM, Quintanal-Villalonga Á, Gao VR, Xie Y, Allaj V, Chaudhary O, Masilionis I, Egger J, Chow A, Walle T, Mattar M, Yarlagadda DVK, Wang JL, Uddin F, Offin M, Ciampricotti M, Qeriqi B, Bahr A, de Stanchina E, Bhanot UK, Lai WV, Bott MJ, Jones DR, Ruiz A, Baine MK, Li Y, Rekhtman N, Poirier JT, Nawy T, Sen T, Mazutis L, Hollmann TJ, Pe'er D, Rudin CM. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021 Nov 08;39(11):1479-1496.e18. doi: 10.1016/j.ccell.2021.09.008. Epub 2021 Oct 14. PMID: 34653364; PMCID: PMC8628860.
Copy Download .nbib Format: NLM
MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer.

iScience

Caeser R, Hulton C, Costa E, Durani V, Little M, Chen X, Tischfield SE, Asher M, Kombak FE, Chavan SS, Shah NS, Ciampricotti M, de Stanchina E, Poirier JT, Rudin CM, Sen T.
PMID: 34712921
iScience. 2021 Oct 05;24(11):103224. doi: 10.1016/j.isci.2021.103224. eCollection 2021 Nov 19.

Activation of mitogenic signaling pathways is a common oncogenic driver of many solid tumors including lung cancer. Although activating mutations in the mitogen-activated protein kinase (MAPK) pathway are prevalent in non-small cell lung cancers, MAPK pathway activity, counterintuitively, is...

Cite
Caeser R, Hulton C, Costa E, et al. MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer. iScience. 2021;24(11):103224doi: 10.1016/j.isci.2021.103224.
Caeser, R., Hulton, C., Costa, E., Durani, V., Little, M., Chen, X., Tischfield, S. E., Asher, M., Kombak, F. E., Chavan, S. S., Shah, N. S., Ciampricotti, M., de Stanchina, E., Poirier, J. T., Rudin, C. M., & Sen, T. (2021). MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer. iScience, 24(11), 103224. https://doi.org/10.1016/j.isci.2021.103224
Caeser, Rebecca, et al. "MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer." iScience vol. 24,11 (2021): 103224. doi: https://doi.org/10.1016/j.isci.2021.103224
Caeser R, Hulton C, Costa E, Durani V, Little M, Chen X, Tischfield SE, Asher M, Kombak FE, Chavan SS, Shah NS, Ciampricotti M, de Stanchina E, Poirier JT, Rudin CM, Sen T. MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer. iScience. 2021 Oct 05;24(11):103224. doi: 10.1016/j.isci.2021.103224. eCollection 2021 Nov 19. PMID: 34712921; PMCID: PMC8528729.
Copy Download .nbib Format: NLM
Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation.

Cancer discovery

Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, Uddin F, Manoj P, Donoghue MTA, Won HH, Chan JM, Ciampricotti M, Chow A, Offin M, Chang JC, Ray-Kirton J, Tischfield SE, Egger JV, Bhanot UK, Linkov I, Asher M, Sinha S, Silber J, Iacobuzio-Donahue CA, Roehrl MH, Hollmann TJ, Yu HA, Qiu J, de Stanchina E, Baine MK, Rekhtman N, Poirier JT, Loomis B, Koche RP, Rudin CM, Sen T.
PMID: 34155000
Cancer Discov. 2021 Jun 21; doi: 10.1158/2159-8290.CD-20-1863. Epub 2021 Jun 21.

Lineage plasticity is implicated in treatment resistance in multiple cancers. In lung adenocarcinomas (LUADs) amenable to targeted therapy, transformation to small cell lung cancer (SCLC) is a recognized resistance mechanism. Defining molecular mechanisms of neuroendocrine (NE) transformation in lung...

Cite
Quintanal-Villalonga A, Taniguchi H, Zhan YA, et al. Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation. Cancer Discov. 2021;doi: 10.1158/2159-8290.CD-20-1863.
Quintanal-Villalonga, A., Taniguchi, H., Zhan, Y. A., Hasan, M. M., Chavan, S. S., Meng, F., Uddin, F., Manoj, P., Donoghue, M. T. A., Won, H. H., Chan, J. M., Ciampricotti, M., Chow, A., Offin, M., Chang, J. C., Ray-Kirton, J., Tischfield, S. E., Egger, J. V., Bhanot, U. K., Linkov, I., Asher, M., Sinha, S., Silber, J., Iacobuzio-Donahue, C. A., Roehrl, M. H., Hollmann, T. J., Yu, H. A., Qiu, J., de Stanchina, E., Baine, M. K., Rekhtman, N., Poirier, J. T., Loomis, B., Koche, R. P., Rudin, C. M., & Sen, T. (2021). Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation. Cancer discovery, . https://doi.org/10.1158/2159-8290.CD-20-1863
Quintanal-Villalonga, Alvaro, et al. "Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation." Cancer discovery vol. (2021). doi: https://doi.org/10.1158/2159-8290.CD-20-1863
Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, Uddin F, Manoj P, Donoghue MTA, Won HH, Chan JM, Ciampricotti M, Chow A, Offin M, Chang JC, Ray-Kirton J, Tischfield SE, Egger JV, Bhanot UK, Linkov I, Asher M, Sinha S, Silber J, Iacobuzio-Donahue CA, Roehrl MH, Hollmann TJ, Yu HA, Qiu J, de Stanchina E, Baine MK, Rekhtman N, Poirier JT, Loomis B, Koche RP, Rudin CM, Sen T. Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation. Cancer Discov. 2021 Jun 21; doi: 10.1158/2159-8290.CD-20-1863. Epub 2021 Jun 21. PMID: 34155000.
Copy Download .nbib Format: NLM
Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages.

Oncoimmunology

Kersten K, Coffelt SB, Hoogstraat M, Verstegen NJM, Vrijland K, Ciampricotti M, Doornebal CW, Hau CS, Wellenstein MD, Salvagno C, Doshi P, Lips EH, Wessels LFA, de Visser KE.
PMID: 28919995
Oncoimmunology. 2017 Jun 19;6(8):e1334744. doi: 10.1080/2162402X.2017.1334744. eCollection 2017.

Patients with primary solid malignancies frequently exhibit signs of systemic inflammation. Notably, elevated levels of neutrophils and their associated soluble mediators are regularly observed in cancer patients, and correlate with reduced survival and increased metastasis formation. Recently, we demonstrated...

Cite
Kersten K, Coffelt SB, Hoogstraat M, et al. Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages. Oncoimmunology. 2017;6(8):e1334744doi: 10.1080/2162402X.2017.1334744.
Kersten, K., Coffelt, S. B., Hoogstraat, M., Verstegen, N. J. M., Vrijland, K., Ciampricotti, M., Doornebal, C. W., Hau, C. S., Wellenstein, M. D., Salvagno, C., Doshi, P., Lips, E. H., Wessels, L. F. A., & de Visser, K. E. (2017). Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages. Oncoimmunology, 6(8), e1334744. https://doi.org/10.1080/2162402X.2017.1334744
Kersten, Kelly, et al. "Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages." Oncoimmunology vol. 6,8 (2017): e1334744. doi: https://doi.org/10.1080/2162402X.2017.1334744
Kersten K, Coffelt SB, Hoogstraat M, Verstegen NJM, Vrijland K, Ciampricotti M, Doornebal CW, Hau CS, Wellenstein MD, Salvagno C, Doshi P, Lips EH, Wessels LFA, de Visser KE. Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages. Oncoimmunology. 2017 Jun 19;6(8):e1334744. doi: 10.1080/2162402X.2017.1334744. eCollection 2017. PMID: 28919995; PMCID: PMC5593698.
Copy Download .nbib Format: NLM
Inhibition of XPO1 sensitizes small cell lung cancer to first- and second-line chemotherapy.

Cancer research

Quintanal-Villalonga A, Taniguchi H, Hao Y, Chow A, Zhan YA, Chavan SS, Uddin F, Allaj V, Manoj P, Shah NS, Chan JM, Offin M, Ciampricotti M, Ray-Kirton J, Egger J, Bhanot U, Linkov I, Asher M, Roehrl MH, Qiu J, de Stanchina E, Hollmann TJ, Koche RP, Sen T, Poirier JT, Rudin CM.
PMID: 34815254
Cancer Res. 2021 Nov 23; doi: 10.1158/0008-5472.CAN-21-2964. Epub 2021 Nov 23.

Small cell lung cancer (SCLC) is an aggressive malignancy characterized by early metastasis and extreme lethality. The backbone of SCLC treatment over the past several decades has been platinum-based doublet chemotherapy, with the recent addition of immunotherapy providing modest...

Cite
Quintanal-Villalonga A, Taniguchi H, Hao Y, et al. Inhibition of XPO1 sensitizes small cell lung cancer to first- and second-line chemotherapy. Cancer Res. 2021;doi: 10.1158/0008-5472.CAN-21-2964.
Quintanal-Villalonga, A., Taniguchi, H., Hao, Y., Chow, A., Zhan, Y. A., Chavan, S. S., Uddin, F., Allaj, V., Manoj, P., Shah, N. S., Chan, J. M., Offin, M., Ciampricotti, M., Ray-Kirton, J., Egger, J., Bhanot, U., Linkov, I., Asher, M., Roehrl, M. H., Qiu, J., de Stanchina, E., Hollmann, T. J., Koche, R. P., Sen, T., Poirier, J. T., & Rudin, C. M. (2021). Inhibition of XPO1 sensitizes small cell lung cancer to first- and second-line chemotherapy. Cancer research, . https://doi.org/10.1158/0008-5472.CAN-21-2964
Quintanal-Villalonga, Alvaro, et al. "Inhibition of XPO1 sensitizes small cell lung cancer to first- and second-line chemotherapy." Cancer research vol. (2021). doi: https://doi.org/10.1158/0008-5472.CAN-21-2964
Quintanal-Villalonga A, Taniguchi H, Hao Y, Chow A, Zhan YA, Chavan SS, Uddin F, Allaj V, Manoj P, Shah NS, Chan JM, Offin M, Ciampricotti M, Ray-Kirton J, Egger J, Bhanot U, Linkov I, Asher M, Roehrl MH, Qiu J, de Stanchina E, Hollmann TJ, Koche RP, Sen T, Poirier JT, Rudin CM. Inhibition of XPO1 sensitizes small cell lung cancer to first- and second-line chemotherapy. Cancer Res. 2021 Nov 23; doi: 10.1158/0008-5472.CAN-21-2964. Epub 2021 Nov 23. PMID: 34815254.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries